Celgene Corp (CELG) 93.93 $CELG
Alkermes Completes Enrolment for Phase II ALKS 3831 Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 5:10PM CDT
Alkermes (ALKS) completed enrolling patients in a study on ALKS 3831.
Final Glance: Biotechnology companies
AP - Thu Sep 04, 4:57PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Watch for Celgene to Potentially Rebound After Falling 1.06% Yesterday
Comtex SmarTrend(R) - Thu Sep 04, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $93.70 to a high of $95.39. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $94.26 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
After Yesterday's Decline of 1.06%, Celgene Offers Investors Better Value
Comtex SmarTrend(R) - Thu Sep 04, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $93.70 to a high of $95.39. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $94.26 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Midday Glance: Biotechnology companies
AP - Thu Sep 04, 12:16PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Thu Sep 04, 9:27AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen
PR Newswire - Thu Sep 04, 7:55AM CDT
On Wednesday, September 03, 2014, the NASDAQ Composite ended at 4,572.57, down 0.56%, the Dow Jones Industrial Average finished the day 0.06% higher at 17,078.28, and the S&P 500 closed at 2,000.72, down 0.08%. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 740.75, up 0.41%, with the index advancing 6.93% in the previous three months. Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Arrowhead Research Corporation (NASDAQ: ARWR), Celgene Corporation (NASDAQ: CELG), and Amgen Inc. (NASDAQ: AMGN). Free research on these five companies can be accessed at:
Phase III FIRST(TM) (MM-020/IFM 07-01) Trial of REVLIMID(R) (lenalidomide) Plus Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplant Published in New England Journal of Medicine
Business Wire - Thu Sep 04, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that data from FIRST (MM-020/IFM 07-01)--an open-label phase III randomized study of continuous REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma (NDMM) who are not candidates for stem cell transplant--have been published in the Sept. 4 issue of the New England Journal of Medicine.
Three Stocks Top-Performing Funds Like: Facebook Baidu Gilead
at Investor's Business Daily - Wed Sep 03, 5:28PM CDT
The new buys list of top-performing funds the past three months showed some heavy buying of top-rated stocks. The nation's leading funds have been stocking up on medical issues, which fared well as the market resumed its uptrend in August. Large...
Is It Time to Buy Celgene Corporation's Stock?
Sean Williams, The Motley Fool - Motley Fool - Wed Sep 03, 10:03AM CDT
To put it lightly, Celgene 's stock has been on fire since the recession ended. Since the market bottomed in on March 9, 2009, Celgene shares have returned 376% as of Friday's close. CELG data by YCharts But can Celgene head even...
Bristol-Myers Returns Clazakizumab Rights, Alder Sinks - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 10:02AM CDT
Bristol-Myers' (BMY) decision to opt out of the development process of clazakizumab caused the shares of Alder (ALDR) to plummet significantly.
Bristol-Myers/Pfizer's Eliquis Encourages in VTE Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:50PM CDT
Encouraging results on Bristol-Myers /Pfizer's (BMY/PFE) Eliquis was presented from an analysis of a phase III study.
Cramer: What's Working, What's Not
at The Street - Tue Sep 02, 11:05AM CDT
Yep, the bets for the rest of 2014 are being placed.
Celgene Shares Up 29.5% Since SmarTrend's Buy Recommendation (CELG)
Comtex SmarTrend(R) - Tue Sep 02, 9:22AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.93. In approximately 4 months, Celgene has returned 29.53% as of today's recent price of $95.77.
Next Resistance Level for Celgene (CELG) is $95.89
Comtex SmarTrend(R) - Tue Sep 02, 9:03AM CDT
Shares of Celgene (NASDAQ:CELG) opened today above their pivot of $94.86 and have already reached the first level of resistance at $95.45. Analysts will be watching for a cross of the next upside pivot targets of $95.89 and $96.92.
Celgene (CELG) On Momo Momentum Watch Today
at The Street - Tue Sep 02, 8:47AM CDT
Trade-Ideas LLC identified Celgene (CELG) as a momo momentum candidate
VentiRx Pharmaceuticals Provides Corporate and Clinical Update
PR Newswire - Tue Sep 02, 7:00AM CDT
VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies, today announced an update on corporate and clinical activities at the company including management structure, commitment for future funding, ongoing clinical trials and future clinical development efforts.
Alkermes Completes Enrolment for Phase II ALKS 3831 Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 5:10PM CDT
Alkermes (ALKS) completed enrolling patients in a study on ALKS 3831.
Final Glance: Biotechnology companies
AP - Thu Sep 04, 4:57PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Watch for Celgene to Potentially Rebound After Falling 1.06% Yesterday
Comtex SmarTrend(R) - Thu Sep 04, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $93.70 to a high of $95.39. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $94.26 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
After Yesterday's Decline of 1.06%, Celgene Offers Investors Better Value
Comtex SmarTrend(R) - Thu Sep 04, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $93.70 to a high of $95.39. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $94.26 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Midday Glance: Biotechnology companies
AP - Thu Sep 04, 12:16PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Thu Sep 04, 9:27AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen
PR Newswire - Thu Sep 04, 7:55AM CDT
On Wednesday, September 03, 2014, the NASDAQ Composite ended at 4,572.57, down 0.56%, the Dow Jones Industrial Average finished the day 0.06% higher at 17,078.28, and the S&P 500 closed at 2,000.72, down 0.08%. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 740.75, up 0.41%, with the index advancing 6.93% in the previous three months. Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Arrowhead Research Corporation (NASDAQ: ARWR), Celgene Corporation (NASDAQ: CELG), and Amgen Inc. (NASDAQ: AMGN). Free research on these five companies can be accessed at:
Phase III FIRST(TM) (MM-020/IFM 07-01) Trial of REVLIMID(R) (lenalidomide) Plus Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplant Published in New England Journal of Medicine
Business Wire - Thu Sep 04, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that data from FIRST (MM-020/IFM 07-01)--an open-label phase III randomized study of continuous REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma (NDMM) who are not candidates for stem cell transplant--have been published in the Sept. 4 issue of the New England Journal of Medicine.
Three Stocks Top-Performing Funds Like: Facebook Baidu Gilead
at Investor's Business Daily - Wed Sep 03, 5:28PM CDT
The new buys list of top-performing funds the past three months showed some heavy buying of top-rated stocks. The nation's leading funds have been stocking up on medical issues, which fared well as the market resumed its uptrend in August. Large...
Is It Time to Buy Celgene Corporation's Stock?
Sean Williams, The Motley Fool - Motley Fool - Wed Sep 03, 10:03AM CDT
To put it lightly, Celgene 's stock has been on fire since the recession ended. Since the market bottomed in on March 9, 2009, Celgene shares have returned 376% as of Friday's close. CELG data by YCharts But can Celgene head even...
Bristol-Myers Returns Clazakizumab Rights, Alder Sinks - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 10:02AM CDT
Bristol-Myers' (BMY) decision to opt out of the development process of clazakizumab caused the shares of Alder (ALDR) to plummet significantly.
Bristol-Myers/Pfizer's Eliquis Encourages in VTE Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:50PM CDT
Encouraging results on Bristol-Myers /Pfizer's (BMY/PFE) Eliquis was presented from an analysis of a phase III study.
Cramer: What's Working, What's Not
at The Street - Tue Sep 02, 11:05AM CDT
Yep, the bets for the rest of 2014 are being placed.
Celgene Shares Up 29.5% Since SmarTrend's Buy Recommendation (CELG)
Comtex SmarTrend(R) - Tue Sep 02, 9:22AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.93. In approximately 4 months, Celgene has returned 29.53% as of today's recent price of $95.77.
Next Resistance Level for Celgene (CELG) is $95.89
Comtex SmarTrend(R) - Tue Sep 02, 9:03AM CDT
Shares of Celgene (NASDAQ:CELG) opened today above their pivot of $94.86 and have already reached the first level of resistance at $95.45. Analysts will be watching for a cross of the next upside pivot targets of $95.89 and $96.92.
Celgene (CELG) On Momo Momentum Watch Today
at The Street - Tue Sep 02, 8:47AM CDT
Trade-Ideas LLC identified Celgene (CELG) as a momo momentum candidate
VentiRx Pharmaceuticals Provides Corporate and Clinical Update
PR Newswire - Tue Sep 02, 7:00AM CDT
VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies, today announced an update on corporate and clinical activities at the company including management structure, commitment for future funding, ongoing clinical trials and future clinical development efforts.
